ArticleFrontiers in immunology2022
NanoNet: Rapid and accurate end-to-end nanobody modeling by deep learning.
Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed.
- Combining AI Structure Prediction and Integrative Modeling for Nanobody-Antigen Complexes.Journal of chemical information and modeling · 2026Article
- Nanobody-based analysis of RhoGTPase stress response inBiotechnology reports (Amsterdam, Netherlands) · 2026Article
- AI-Driven Design Platforms of Next-Generation Antibody Therapeutics.Topics in current chemistry (Cham) · 2026Review
- Repertoire-scale antibody structural prediction informs therapeutic design.Science advances · 2026Article
- Artificial intelligence in immunotherapy: revolutionizing diagnostic and therapeutic applications in cancer and autoimmune diseases.Clinical and experimental medicine · 2026Review
- Article
- Applications of Artificial Intelligence in Biotech Drug Discovery and Product Development.MedComm · 2025Review
- Nanobodies: From Discovery to AI-Driven Design.Biology · 2025Review
- Finding antibodies in cryo-EM maps with CrAI.Bioinformatics (Oxford, England) · 2025Article
- Unveiling the new chapter in nanobody engineering: advances in traditional construction and AI-driven optimization.Journal of nanobiotechnology · 2025Review
- Nanobody engineering: computational modelling and design for biomedical and therapeutic applications.FEBS open bio · 2025Review
- Computational electrostatic engineering of nanobodies for enhanced SARS-CoV-2 receptor binding domain recognition.Frontiers in molecular biosciences · 2025Article
- A comprehensive overview of recent advances in generative models for antibodies.Computational and structural biotechnology journal · 2024Review
- NABP-BERT: NANOBODY®-antigen binding prediction based on bidirectional encoder representations from transformers (BERT) architecture.Briefings in bioinformatics · 2024Article
- Prediction of antibody-antigen interaction based on backbone aware with invariant point attention.BMC bioinformatics · 2024Article
- Recent Advances in Artificial Intelligence to Improve Immunotherapy and the Use of Digital Twins to Identify Prognosis of Patients with Solid Tumors.International journal of molecular sciences · 2024Review
- TEMPRO: nanobody melting temperature estimation model using protein embeddings.Scientific reports · 2024Article
- P-NADs:Heliyon · 2024Article
- Article
- Human coronavirus OC43 nanobody neutralizes virus and protects mice from infection.Journal of virology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antibodies are a rapidly growing class of therapeutics. Recently, single domain camelid VHH antibodies, and their recognition nanobody domain (Nb) appeared as a cost-effective highly stable alternative to full-length antibodies. There is a growing need for high-throughput epitope mapping based on accurate structural modeling of the variable domains that share a common fold and differ in the Complementarity Determining Regions (CDRs). We develop a deep learning end-to-end model, NanoNet, that given a sequence directly produces the 3D coordinates of the backbone and C
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.